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Abstract
Background: Purinergic receptor-mediated signaling plays an important role in the function of glial cells, including
glial tumor cells. Bradykinin is also an important paracrine mediator which is highly expressed in brain tumors and
may correlate with their pathological grade. Interaction between bradykinin and purinergic signaling may therefore
be involved in the regulation of glial tumor cells.
Results: We examined the effect of bradykinin on glial purinergic signaling in an immortalized glioma cell line.
Confocal calcium imaging revealed that ATP evokes an increase in [Ca2+]i in the U87 human astrocytoma cell line.
This response was reduced with repetitive application of ATP, likely due to receptor desensitization. However
exposure to bradykinin increased the Ca2+ response to a second application of ATP, consistent with increased
resensitization. The bradykinin effect on resensitization was similar in the absence of extracellular Ca2+ or in the
presence of the PKC activator PMA, but was inhibited by the protein phosphatase inhibitor okadaic acid and the
PI3K inhibitor LY294002.
Conclusions: Modulation of protein phosphatases and the PI3K pathway may represent a mechanism by which
bradykinin potentiates purinergic signaling in glial cells.
Background
ATP is a primary extracellular signaling molecule for
glial cells in the CNS [1,2]. In astrocytes, ATP is a key
messenger for the intercellular communication of cal-
cium waves, in which increases in [Ca2+]i propagate
from cell to cell across multiple cells [3-5]. Glial cell cal-
cium waves have been characterized extensively in vitro
in a variety of different tissue preparations, and also
more recently in vivo in rodent cortex and retina [6-10].
They are thought to play physiological roles in the mod-
ulation of neuronal activity and vascular function, in
addition to contributing to pathological processes such
as cortical spreading depression and seizures [11,12].
Purinergic signaling is also believed to play an important
role in the development and proliferation of glial cells
under both physiological and pathological conditions,
including those associated with glial tumors [13-15].
Glial cells respond to ATP through P2 purinergic
receptors that belong to two families: P2Y G protein-
coupled receptors (GPCR) and P2X ligand gated ion
channels. Activation of P2Y purinergic receptors triggers
G-protein mediated activation of phospholipase C g
(PLCg) and increases levels of inositol 1,4,5-triphosphate
(IP3) and diacylglycerol (DAG), leading to elevations in
intracellular calcium concentration and the activation of
protein kinase C (PKC). By contrast, activation of P2X
purinergic receptors leads to an increase in intracellular
calcium concentration by influx of extracellular calcium
through the receptor channel. In glial cells, the sus-
tained increase in [Ca2+]i evoked by ATP is mediated
predominantly via activation of P2Y purinergic recep-
tors, although the response to higher concentrations of
ATP may also involve Ca2+ influx through P2X recep-
tors [1].
Activation of GPCRs by agonists not only results in
the G protein- dependent activation of the effector sys-
tem, but also triggers coordinated molecular mechan-
isms governing the ongoing response of the receptors to
further stimulation [16,17]. GPCR receptors show
attenuation or loss of responses by repetitive agonist
exposure, referred to as desensitization. Reduction of
GPCR responsiveness to an agonist over time represents
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an important physiological feedback mechanism that
protects against both acute and chronic receptor oversti-
mulation. After a period of desensitization, receptors
recover their responses to agonists (resensitization),
which enables receptors to maintain their ability to
respond to agonists over time [17].
GPCR desensitization involves multiple distinct events
including the uncoupling of receptors from their G pro-
teins, the internalization and sequestration of receptors
to endosomes, and down-regulation [16]. Receptor G
protein uncoupling in response to receptor phosphoryla-
tion is the most rapid means of attenuating GPCR
responsiveness and occurs within seconds to minutes
following agonist activation. Phosphorylation is mediated
by two families of protein kinases: the second messenger
dependent protein kinases (e.g. PKA, PKC) and the G
protein-coupled receptor kinases GRPKs; [18]. Receptor
sequestration is also initiated within seconds to minutes
of receptor activation and potentially contributes to
receptor desensitization by limiting the number of
plasma membrane accessible receptor binding sites.
Down-regulation, a decrease in the total cellular com-
plement of GPCRs, occurs in response to longer-term
exposure to agonist from minutes to hours [18]. Resen-
sitization of receptors involves the reversal of these pro-
cesses, namely receptor dephosphorylation by
phospatases, recovery of sequestered receptors to the
plasma membrane, and increased synthesis and or traf-
ficking of receptors to their sites of function [17].
Bradykinin is a nonapeptide (or kinin) formed from
precursors (kininos) through actions of plasma and tis-
sue kallikreins [19]. Kinins are implicated in physiologi-
cal and pathological processes such as vasodilatation
and inflammation [19]. Two kinin-specific GPCR have
been reported, B1R and B2R. The B1R mediates the
actions of Lys-des-Arg9- bradykinin whereas B2R is acti-
vated by the main kinin, bradykinin [19,20]. Activation
of B2R is preferentially coupled to G proteins of the
Ga-q subtypes, which in turn activate PLCb, leading to
production of IP3 and release of intracellular calcium
[19,20]. B2R activation also activates PKC, phosphatase
A2, phospholipase C, and phosphoinositide 3-kinase
(PI3K), and stimulates production of nitric oxide
[19,20]. B2R’s are expressed in many different cells
including astrocytes [19-25] and human astrocytic
tumors [26,27]. It has been reported that B2 receptors
are more highly expressed in glioma cells as compared
with normal astrocytes [28] and the level of expression
of B2 receptors may be correlated with the grade of
human gliomas [29].
Bradykinin and ATP-mediated signaling may interact
via multiple pathways. Bradykinin potentiates the ATP
response in Xenopus oocytes that express P2X receptors
[30]. Meanwhile, ATP causes a desensitization of B2R in
a neuroblastoma cell line [31] and bradykinin promotes/
induces ATP release from astrocytes [32]. In this work,
we explore the effects of bradykinin on purinergic
receptor signaling in the U87 human astrocytoma cell
line. We show that bradykinin promotes resensitization
of P2Y purinergic receptors via activation of PI3K and
the phosphatase A2 pathways.
Methods
Cell culture
Human astrocytoma U87 cells were grown in DMEM/
F12 mixture (50-50) medium supplemented with 10%
(V/V) fetal calf serum, 100 units/ml penicillin, and 10
mg/ml streptomycin in humidified air with 5% CO2 at
37°C. 1 × 106 cells were grown to sub-confluent density
on Poly-D-lysine treated round glass cover slips (18 mm
diameter) for 4-6 days prior to experimentation.
Measurement of [Ca2+]i
Cells were loaded with 5 μM fluo-4-AM for 20 min at
room temperature in Hanks Buffered Saline Solution
(HBSS) with HEPES (pH 7.38) that was used as the stan-
dard experimental solution. All experiments were per-
formed with constant perfusion (2 ml/min) at room
temperature (22°C) on a Nikon Diaphot microscope
coupled to a custom confocal imaging system as pre-
viously described [33]. Briefly, excitation from a 475 nm
diode laser was delivered via scanning mirrors to the spe-
cimen through a 40× lens. Fluorescence emission was
gathered through a dichroic mirror and 535 bandpass fil-
ter to a photomultiplier tube (Hamamatsu) and images
were acquired at 1 Hz for 6 minutes by an image acquisi-
tion board (Bitflow Raven) controlled by Video Savant
software. Before application of test substances, cells were
continuously perfused for 10 minutes with standard solu-
tion. Ligands were added for the duration specified by
continuous perfusion. For dose-response relationships of
bradykinin, the compound was applied for 5 minutes.
Bradykinin Pretreatment and Repetitive ATP application
After exposure to either control solution or 200 nM
bradykinin for 5 minutes, cells were then washed for 10
minutes with HBSS-HEPES, after which ATP (10 μM)
was applied for 1 minute, ATP was washed off for 2
minutes, followed by a second 1-minute application of
ATP. The PKC activator PMA (1 μM), the BK2R
antagonist HOE-140 (1 μM), and the phosphatase and
kinase inhibitors (Okadaic acid, 40 nM and LY294002,
50 μM, respectively) were applied for 10 minutes prior
to application of bradykinin. All chemicals were dis-
solved in HBSS-HEPES. For experiments with Ca2+ free
medium, ATP was applied in HBSS-HEPES containing
no added Ca2+, after which cells were returned to nor-
mal HBSS-HEPES.
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Analysis
Regions of interest (30 × 30 pixels) were placed in the
center of the cell body of every single cell in each
microscopic field, and fluo4 fluorescence vs. time was
determined for each cell using ImageJ and Origin 6.0
software (Northampton, MA, USA). Ca2+ responses
were characterized based on ΔF/Fo calculated as (F1 -
F0)/F0, where F1 is the fluorescence at a given time and
F0 is the basal mean fluorescence 1 minute before of
application of test substances. Peak Δ/Fo was deter-
mined for each individual cell for each ATP application,
and these peak responses were compared for individual
cells to determine the extent of resensitization. The area
under the curve (AUC) for each [Ca2+]i response was
also quantified using Origin software and values for
AUC were also compared for the 1st and 2nd ATP
response as an indication of resensitization. The ratio of
the peak Δ/Fo or AUC for the 2
nd vs. 1st response to
ATP was designated as the % resensitization for each
cell, and these values were averaged for all cells. A sig-
moidal dose-response curve was fitted by Origin 6.0
(Northampton, MA, USA). Statistical analysis was per-
formed using GraphPad Prizm 4.0 (La Jolla, CA, USA).




Since activation of B2R leads to release of intracellular
calcium [19,20], we first determined the concentration
that evoked the maximum [Ca2+]i response in U-87
cells. Results from those experiments (Figures 1A-B)
showed that maximum averaged peak response reached
a plateau at 200 nM of bradykinin, we therefore used
this concentration to investigate the effects of bradyki-
nin on the response to ATP. [Ca2+]i was monitored for
10 minutes following bradykinin exposure. After the
initial response to bradykinin, no further changes in
[Ca2+]i were observed over the next 10 minutes.
Desensitization and Resensitization of ATP receptors
GPCR, including P2Y purinergic receptors, undergo
desensitization and resensitization after agonist exposure
[18]. We investigated whether bradykinin can affect
these processes. When U-87 glioma cells were exposed
to repetitive 1 minute application of ATP (10 μM) sepa-
rated by two minutes, the response for the second appli-
cation of ATP showed a reduced [Ca2+]i response
(Figure 1C). Cells incubated with bradykinin (200 nM
for 5 minutes) and then exposed to the same double
application of ATP, ten minutes later, also showed a
reduced [Ca2+]i response. However, the peak and the
AUC for second response to ATP were significantly (p <
0.001) larger than in control cells (Figure 1D),
suggesting that previous exposure to bradykinin signifi-
cantly increased the resensitization of P2Y receptors.
To confirm that the activation of BK2R is necessary
for the increase in the resensitization of the ATP recep-
tors, we applied the selective BK2R antagonist, HOE-
140 (1 μM) concurrently with bradykinin application.
Cells treated with HOE-140 plus bradykinin showed no
differences in the responses to ATP with respect to the
control cells (standard solution); moreover, the evoked
increase in the resensitization of the second response to
ATP observed in the group with bradykinin alone was
significantly blocked (p < 0.001, Figures 2A-B)
Application of ATP (10 μM) consistently evoked an
increase in [Ca2+]i in U87 cells. This response was
blocked by pretreatment with the PLC inhibitor U73122
(10 μM) and was not inhibited by the removal of extra-
cellular Ca2+, indicating that the response was mediated
primarily by G-protein coupled purinergic (P2Y) recep-
tors as has been previously described [1].
To examine the contribution of extracellular calcium
to the ATP resensitization, similar experiments were
performed in Ca2+ free medium. When ATP was applied
in 0 Ca2+ medium, the amplitude of the first ATP
response was not significantly different from those
observed in normal Ca2+ medium (figures 3A-B), sug-
gesting that the response was due to release of Ca2 from
intracellular stores. The increase in resensitization we
observed with bradykinin application was also preserved
in 0 Ca2+ medium, although a significantly smaller peak
amplitude (39% average resensitization in 0 Ca2+ vs.
55% average resensitization in normal Ca2+ medium,
Figure 2A, p < 0.001). These results indicate that Ca2+
influx is important for the resensitization of the
response to ATP, likely in part by replenishing intracel-
lular Ca2+ stores. However, Ca2+ influx through P2X
receptors or other Ca2+ influx pathways is not required
for the increased resensitization of the ATP response
that is mediated by bradykinin.
To investigate the role of phosphorylation in the
resensitization of GPCR/P2Y in response to bradykinin,
we applied the PKC activator phorbol 12-myristate 13-
acetate (PMA, 1 μM) for 10 minutes prior to the appli-
cation of bradykinin (15 minutes before the first ATP
application). Treatment with PMA significantly
(p <0.001) reduced the peak amplitude of the first ATP
response in both bradykinin treated and untreated cells
by about 40%, with no significant difference between
groups (Figures 3A). PMA treatment also significantly
(p < 0.001) reduced resensitization of the ATP response
in both groups. However, the bradykinin treated cells
still showed significantly (p < 0.05) greater resensitiza-
tion as compared with untreated cells (Figures 2A-B).
These results indicate that activation of PKC signifi-
cantly inhibits ATP mediated Ca2+ signaling and reduces
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resensitization of the response to ATP. However, the
effect of bradykinin on the resensitization of the ATP
response continues to occur following activation of PKC
by PMA.
The role of phosphatases in the GPCR/P2Y response
was tested with okadaic acid (40 nM), a protein phos-
phatase 1 and 2A inhibitor. Okadaic acid did not have a
significant effect on the initial response to ATP in bra-
dykinin-treated and control cells (Figures 3A-B). How-
ever, okadaic acid blocked the bradykinin -evoked
increase in resensitization of the second response to
ATP (Figures 2A-B).
To determine the potential involvement of the PI3K
pathway in the resensitization response to bradykinin,
we applied the PI3K inhibitor LY294002 (50 μM) to
both control and bradykinin -treated cells. LY294002
significantly (p < 0.001) inhibited both the initial
response to ATP (Figures 3A-B) as well as the resensiti-
zation of the response to the second application of ATP.
Treatment with LY294002 also inhibited the effect of
Figure 1 Response of U-87 cells to Bradykinin. (A) Superimposed line traces show the calcium increase upon exposure to different
concentrations of bradykinin. The traces are the fluo4 ΔF/F vs. time for representative cells. (B) Dose-response relationships of bradykinin. Each
value represents the average peak value of ΔF/F from 78-276 cells for each concentration tested. The average peak values for each concentration
were fitted with sigmoidal dose-response and EC50 obtained was 6.7 nM of bradykinin. The maximum response was reached with 200 nM. (C)
Typical Ca2+ response to repetitive application of ATP (10 μM). Line trace shows fluo4 ΔF/F vs. time for a representative cell. Note that the
amplitude of the increase in [Ca2+]i in response to the second application ATP is significantly reduced as compared with the first application. (D).
Typical Ca2+ response to ATP in a cell pre-treated with bradykinin (200 nM). Pre treatment with bradykinin did not results in any significant
change in the response to fist exposure to ATP, however, the second response to ATP showed an increase in the amplitude as compared with
untreated cells (C).
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Figure 2 Mechanisms of bradykinin effects on ATP resensitization. Graph A shows the average (± SEM) of ratio of the peak Ca2+ response
and graph B shows the average (± SEM) ratio of the area under the curve (AUC) of the Ca2+ response of the second ATP response for all
conditions tested. The ratio of the peak Δ/Fo (A) or AUC (B) for the 2
nd vs. 1st response to ATP was designated as the % resensitization for each
cell, and these values were averaged for all cells. Statistical significance was obtained using one way ANOVA with post-hoc Turkey. ***p < 0.001,
**p < 0.01 and *p < 0.05, denotes statistic significance. Note that the enhancement of resensitization persisted on removal of extracellular Ca2+,
but is lost on inhibition of phosphatases with okadaic acid, and by inhibition of PI3 kinase with LY294002.
Figure 3 The first ATP response in bradykinin-treated vs. untreated cells. A and B graphs shows the average ratio (± SEM) of the peak Ca2+
response and the average (± SEM) of area under the curve (AUC) of the Ca2+ response of the first ATP response for all conditions tested (n =
47-276 cells per condition). Statistical significance was obtained using one way ANOVA with post-hoc Turkey. ***p < 0.001, **p < 0.01 and *p <
0.05, denotes statistic significance compared with control.
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bradykinin on resensitization of the ATP response.
(Figures 2A-B)
Discussion
Purinergic receptor-mediated signaling is critically
important for the function of many cell types [1,2], but
relatively little is known about the process by which
purinergic signaling interacts with other types of recep-
tor-mediated signaling. Given the potential importance
for this kind of interaction, especially in glial tumors, we
investigated the role of bradykinin signaling on puriner-
gic signaling in the human glioma cell line.
In U87 astrocytoma cells, the preincubation with bra-
dykinin had no significant effect on the peak amplitude
and area under the curve (AUC) in the first response to
ATP. However both peak amplitude and AUC of the
response to second application of ATP were significantly
increased by bradykinin. That this effect was blocked by
the bradykinin the specific antagonist HOE 140, confirm
that the resensitization phenomenon we observed is
mediated by the activation of bradykinin receptors.
The calcium response of U87 cells to ATP is mediated
primarily by P2Y purinergic receptors, as shown by the
persistence of the response in zero Ca2+ solution, as
well as the complete inhibition of the response in cells
treated with the PLC inhibitor U73122. The persistence
of the bradykinin -induced increase in resensitization of
the Ca2+ response to ATP in the absence of extracellular
Ca2+ indicates that the entry of calcium through P2X
receptors or other Ca2+ influx pathways is not required
for the effect of bradykinin on resensitization. Because
bradykinin activates PKC, we investigated the effects of
the PKC activator phorbol ester on ATP mediated cal-
cium signaling and its modulation by bradykinin. Similar
to the reports of others [34], we found that treatment
with phorbol ester significantly reduced the initial
response to ATP, and increased desensitization of the
response. However, the increased resensitization of the
ATP response in bradykinin treated cells was main-
tained, suggesting that PKC did not play a primary role
in the bradykinin effect.
The resensitization effect of bradykinin was abolished
by the phosphatase 1 and 2A inhibitor okadaic acid, con-
sistent with a key role for dephosphorylation of P2Y puri-
nergic receptors in the increased resensitization induced
by bradykinin. Other investigators [34-36] have also
found that phophatases are important for the resensitiza-
tion of P2Y purinergic receptors, and their blockage with
okadaic acid decreases receptor resensitization [36].
Our additional finding that the bradykinin effect was
prevented by inhibition of PI3K with LY294002 is con-
sistent with previous reports of a role for PI3K in resen-
sitization of P2Y purinergic receptors in guinea pig
Muller cells [37]. PI3K has been found to mediate
phosphorylation and translocation of phospholipase C-
gamma and resultant IP3 production in response to
activation of P2Y purinergic receptors - this could be
one mechanism by which PI3 kinase inhibitors inhibit
both the initial response to ATP and the resensitization
of P2Y purinergic receptors [38].
Resensitization of GPCR’s may occur both through re-
coupling of receptors to G proteins, as well as agonist-
dependent endocytosis of the receptor to endosomal
compartment followed by dephosphorylation and recy-
cling back to the membrane as a functional receptor
[18]. The U87 cells mainly express P2Y1 purinergic
receptors [39] and it has recently been reported that
agonist-mediated endocytosis of P2Y1 purinergic recep-
tors occurs over a period of 30 minutes, with recycling
of endocytosed receptors occurring over a period of
approximately 60 minutes [40]. The duration of this
process is therefore significantly greater than the 1 min-
ute time period over which we observed increased
resensitization of the ATP response in bradykinin trea-
ted cells. Thus, the effect of bradykinin that we observed
is more likely to be due to a re-coupling of the receptor
to G protein prior to recycling through the endosomal
compartment.
The effects of bradykinin on ATP-mediated signaling
could play multiple functional roles in the nervous sys-
tem. B2 receptors are highly expressed on glioma cells,
and the expression of these receptors may be correlated
with tumor grade [29], suggesting that they may play a
role in the abnormal growth and migration of these
cells [28]. P2Ypurinergic receptors have also been impli-
cated in the growth and migration of glial tumors
[41-43]. Thus, potentiation of purinergic receptor signal-
ing by bradykinin could play a role in CNS tumor for-
mation and progression.
B2 receptors have also been a focus of investigation
and potential therapies because of their role in opening
the blood-tumor-barrier [44]. P2Y purinergic receptors
are also highly expressed at the glio-vascular interface,
suggesting that an interaction between bradykinin and
P2Y purinergic receptors could play a role in the inter-
action of glioma cells with the vasculature [45]. Bradyki-
nin is also well known as an important inflammatory
mediator, with potential roles in the response of the
brain to head injury, encephalitis, and ischemia [46].
Significant quantities of ATP may be released in associa-
tion with these same events, which therefore represent
other settings in which interaction between bradykinin
and ATP-mediated signaling may be important [47].
Finally, both B2 and P2Y purinergic receptors may be
involved in pain transmission. Bradykinin released in the
setting of tissue damage or inflammation could therefore
influence nociception by increased resensitization of P2Y
purinergic receptors [48,49].
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Conclusions
Our results indicate that bradykinin-evoked signaling
has a significant influence on purinergic receptor signal-
ing via the PI3 kinase pathway. Potentiation of puriner-
gic signaling by increasing receptor resensitization may
represent an important mechanism by which bradykinin
modulates glial cell function.
Abbreviations
[Ca2+]i: intracellular calcium concentration; ATP: adenosine 5’ triphosphate;
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